You are here: Industry Insights > Market News > Jawed Zia joins Abbott as VP, Established Pharmaceuticals, India

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Vibegron Intermediate CAS:1421271-01-3

Food Grade Fish Collagen

Vibegron Intermediate CAS:1295539-30-8

Vibegron Intermediate CAS:1426235-01-9

Vibegron Intermediate CAS:163625-46-5

Vibegron Intermediate

Jawed Zia joins Abbott as VP, Established Pharmaceuticals, India

financialexpressJune 01, 2018

Tag: Jawed Zia , VP , Established Pharmaceuticals

Favorites

Abbott has appointed Jawed Zia as VP, Established Pharmaceuticals, India. Reportedly, in this role, Zia will lead Abbott’s India pharma business. He will be responsible for Abbott’s continued growth and leadership in the country.

Zia joins Abbott from Novartis where he was the Pharma Division Head of Novartis Pharmaceuticals and Country President. Over the last 25 years of his career, Zia has been in various leadership roles with Novartis, working in its pharma and ophthalmic businesses, as well as being part of many integration projects. He has had the opportunity to work in several countries including Singapore, Turkey and Saudi Arabia.

Register as Visitor to CPhI China 2018!

Previous:Serum Institute of India and Intravacc to develop Bioneedles

Next:Sanofi Genzyme partners with MSSI to support multiple sclerosis community

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Jawed Zia joins Abbott as VP, Established Pharmaceuticals, India | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Jawed Zia joins Abbott as VP, Established Pharmaceuticals, India

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Jawed Zia joins Abbott as VP, Established Pharmaceuticals, India

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>